The European Commission has approved Roche’s blockbuster cancer drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for adult patients with hepatocellular carcinoma (HCC) that is advanced or unable to be removed by surgery.

The approval was based on a phase 3 study showing the combination reduced the risk of mortality by 42 percent and reduced the risk of disease progression or death by 42 percent vs. the control.

The drug received a recommendation from the EMA’s Committee for Medicinal Products for Human Use in September. Earlier this year, the FDA approved the combination of Tecentriq and Avastin for the treatment of HCC.

Tecentriq posted global sales in 2019 of more than $2 billion.